After the ‘Meaningful Vote’, MHRA guidance in event of a no-deal Brexit scenario

Following the ‘Meaningful Vote’ on the 15th of January, in which MPs voted down the Prime Minister Theresa May’s Brexit Deal, Aptus Clinical would like to reiterate the updated guidance from the MHRA in the event of a no deal…

Aptus Clinical receive £150k from NPIF-FW Capital Debt Finance

Aptus Clinical, a specialist clinical contract research organisation based at Alderley Park, has received a £150k loan from the Northern Powerhouse Investment Fund (NPIF) – FW Capital Debt Finance, managed by FW Capital and part of the NPIF. The growth…

Cell & Gene Therapy Catapult Partnership

APTUS CLINICAL AND THE CELL AND GENE THERAPY CATAPULT ANNOUNCE THEIR CLINICAL SERVICE PARTNERSHIP TO SUPPORT ADVANCED THERAPY DEVELOPMENT IN THE UK Following a rigorous selection process Aptus Clinical have been appointed as a supplier for Clinical Services by the…

Do you know our Values?

Great to see our friends at Blueberry Therapeutics achieve this

http://www.blueberrytherapeutics.com/blueberry-therapeutics-limited-closes-10m-funding-to-support-development-of-nanomedicines-portfolio/

Aptus Clinical delighted by MHRA announcement on CTR

MHRA update on Clinical Trials Regulation Aptus Clinical are delighted at the MHRAs announcement this week that the UK will follow the EU Clinical Trials Regulation (CTR) when it is implemented in 2020. This provides much needed reassurance for us…

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

Press Release Artelo Biosciences ENTERS INTO GLOBAL R&D PARTNERSHIP WITH SYNGENE INTERNATIONAL and APTUS CLINICAL for the clinical development of ART27.13 in oncology LA JOLLA, CA – June 5, 2018 – Artelo Biosciences, Inc. (OTCQB: ARTL), a biopharmaceutical company focused…

CEO gives a talk at the Advanced Therapies & Regenerative Medicine Congress

Aptus Clinical CEO Steve McConchie discusses Aptus Clinical and their role in iMATCH at the World Advanced Therapies & Regenerative Medicine Congress May 2018. https://twitter.com/aptusclinical/status/999983518720712704

Aptus Clinical Awarded Part of £7m Government Investment

Manchester-based Aptus Clinical are one of twelve partners receiving government funding to ensure that more patients benefit from a new generation of medicines. Nearly £7m has been awarded to the Innovate Manchester Advanced Therapy Centre Hub (iMATCH) by Innovate UK…

Delighted to be part of iMATCH

A recently formed Manchester health consortium, led by The Christie, has been awarded nearly £7 million of funding to ensure more patients benefit from a new generation of disease-fighting drugs for cancer and non-cancer illnesses. Manchester is one of only…